GlassScriptPhysician profile
Lawrence Gensler
NPI 1841295953
$31,105.05
in general payments reported to CMS, 2019-2025
35 companies · $1,946 in 2025
The $1,946 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,973 · 2020: $7,658 · 2021: $5,106 · 2022: $2,265 · 2023: $1,772 · 2024: $3,385 · 2025: $1,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,028 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,027.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,075.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $8,658.84 | 2019-2020 | |
| Abbvie INC. | $7,594.60 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $5,817.47 | 2019-2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $1,242.34 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,088.05 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $1,033.57 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $1,001.71 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $828.96 | 2019-2022 | |
| Celgene Corporation | $444.79 | 2021-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $426.49 | 2020-2023 | Stelara |
| Intercept Pharmaceuticals, INC. | $397.26 | 2019-2025 | |
| Pfizer INC. | $324.54 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $305.68 | 2021-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $283.98 | 2019-2024 | Dificid |
| Qol Medical, LLC | $266.98 | 2019-2025 | Sucraid, Sucraid |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $204.96 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $157.09 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $156.83 | 2025 | Dupixent |
| Boston Scientific Corporation | $133.54 | 2022-2024 | Captivator II, Radial Jaw 4, Resolution 360 Clip |
| Novo Nordisk INC | $132.24 | 2024-2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $115.00 | 2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $107.15 | 2019-2023 | Rebyota |
| Celltrion USA INC. | $104.86 | 2024-2025 | Vegzelma |
| Gilead Sciences, INC. | $66.79 | 2019-2021 | |
| Evoke Pharma, INC. | $27.20 | 2021-2022 | |
| Organon LLC | $27.19 | 2023-2025 | Hadlima |
| Amgen INC. | $22.13 | 2023 | Avsola |
| Alfasigma USA, INC. | $20.38 | 2020 | |
| Madrigal Pharmaceuticals | $18.77 | 2025 | Rezdiffra |
| Shionogi INC | $18.31 | 2019 | |
| Ucb, INC. | $17.35 | 2020 | |
| Redhill Biopharma INC. | $16.10 | 2023 | Talicia, Movantik, Aemcolo |
| Mauna Kea Technologies, INC. | $16.02 | 2024 | |
| Intra-Sana Laboratories | $15.80 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Braintree Laboratories, INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Gensler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.